LRRK2, Polyclonal Antibody

leucine-rich repeat kinase 2

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Purified by site-modified Epitope Affinity Purification.

Supplied in sterile Tris-buffered saline (pH7.2) containing antibody stabilizer.

The antibodies are stable for 12 months from date of receipt when stored at -20 degree C. The antibodies can be stored at 2 degree C - 8 degree C for one month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

Small volumes of anti-LRRK2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

N/A

ELISA (EIA), Flow Cytometry (FC/FACS), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB)

ELISA: 0.01-0.1 ug/ml
Flow Cytometry: 5-10 ug/ml
Immunohistochemistry: 2-10 ug/ml
Immunoprecipitation: 2-5 ug/ml
Western Blot: 0.1-1 ug/ml

286,103 Da

leucine-rich repeat kinase 2

leucine-rich repeat serine/threonine-protein kinase 2

Leucine-rich repeat serine/threonine-protein kinase 2

PARK8  [Similar Products]

LRRK2: a large multidomain protein kinase with a TKL-type kinase domain, multiple protein-protein interaction domains and a mitochondrial Rho domain (MIRO). May play a role in the etiology of Parkinson disease. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Interacts with PARK2, PRDX3 and TPCN2. Expressed throughout the ***** brain, but at a lower level than in heart and liver. Expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

Protein type: EC 2.7.11.1; Kinase, protein; LRRK family; Protein kinase, Ser/Thr (non-receptor); Protein kinase, TKL; TKL group

Chromosomal Location of Human Ortholog: 12q12

Cellular Component: axon; cell soma; cytoplasm; cytoplasmic vesicle; cytosol; dendrite; dendrite cytoplasm; endoplasmic reticulum; endosome; extracellular space; Golgi apparatus; Golgi-associated vesicle; growth cone; inclusion body; intracellular; intracellular membrane-bound organelle; lysosome; microvillus; mitochondrial inner membrane; mitochondrial matrix; mitochondrial membrane; mitochondrial outer membrane; mitochondrion; neuron projection; nucleus; perikaryon; plasma membrane; terminal button

Molecular Function: actin binding; clathrin binding; glycoprotein binding; GTP binding; GTP-dependent protein kinase activity; GTPase activator activity; GTPase activity; identical protein binding; kinase activity; MAP kinase kinase activity; microtubule binding; protein binding; protein homodimerization activity; protein kinase A binding; protein kinase activity; protein serine/threonine kinase activity; receptor signaling complex scaffold activity; Rho GTPase binding; SNARE binding; syntaxin-1 binding; tubulin binding

Biological Process: activation of MAPK activity; activation of MAPKK activity; calcium-mediated signaling; cellular response to starvation; determination of ***** life span; endocytosis; Golgi organization and biogenesis; GTP metabolic process; intracellular distribution of mitochondria; lysosome organization and biogenesis; MAPKKK cascade; mitochondrion localization; mitochondrion organization and biogenesis; negative regulation of macroautophagy; negative regulation of protein amino acid phosphorylation; negative regulation of protein binding; neurite morphogenesis; neuromuscular junction development; olfactory bulb development; peptidyl-serine phosphorylation; peptidyl-threonine phosphorylation; phosphorylation; positive regulation of autophagy; positive regulation of dopamine receptor signaling pathway; positive regulation of MAP kinase activity; positive regulation of programmed cell death; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein amino acid phosphorylation; positive regulation of protein binding; positive regulation of protein ubiquitination; protein amino acid autophosphorylation; protein amino acid phosphorylation; regulation of autophagy; regulation of dopamine receptor signaling pathway; regulation of excitatory postsynaptic membrane potential; regulation of locomotion; regulation of membrane potential; regulation of mitochondrial depolarization; regulation of neuron maturation; regulation of synaptic transmission, glutamatergic; response to oxidative stress; tangential migration from the subventricular zone to the olfactory bulb; Wnt receptor signaling pathway through beta-catenin

Disease: Parkinson Disease 8, Autosomal Dominant

N/A

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.